Abbott LaboratoriesABT +0.94%80 EV-to-FCF is 25.93 as of Jun. 27, 2026, which is 21% below its 10-year median of 32.92. GuruFocus rates ABT with a GF Score™ of 80/100 and a GF Value™ of $129.49 (Modestly Undervalued). Among 421 Medical Devices & Instruments companies, Abbott Laboratories ranks worse than 55.82% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Abbott Laboratories's Enterprise Value is $191,331 Mil.
Abbott Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $7,378 Mil. Therefore, Abbott Laboratories's EV-to-FCF for today is 25.93.
The historical rank and industry rank for Abbott Laboratories's EV-to-FCF or its related term are showing as below:
ABT'
s EV-to-FCF Range Over the Past 10 Years
Min: 20.42 Med: 32.92 Max: 47.66
Current: 25.93
During the past 13 years, the highest EV-to-FCF of Abbott Laboratories was 47.66. The lowest was 20.42. And the median was 32.92.
ABT's EV-to-FCF is ranked worse than 55.82% of 421
companies
in the Medical Devices & Instruments industry
Industry Median: 22.82
vs ABT: 25.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Abbott Laboratories's PE Ratio (TTM) for today is calculated as:
Abbott Laboratories's share price for today is $94.12.
Abbott Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.570.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Abbott Laboratories EV-to-FCF Related Terms
Abbott Laboratories EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Abbott Laboratories's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's EV-to-FCF falls into.
Abbott Laboratories's current Enterprise Value is $191,331 Mil.
Abbott Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7,378 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (ABT) has a EV-to-FCF of 25.93 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Abbott Laboratories and its competitors. This is 21% below median its historical median of 32.92. Over the past decade, Abbott Laboratories' EV-to-FCF has ranged from 20.42 to 47.66. According to the industry distribution chart, Abbott Laboratories ranks #235 out of 421 companies in the Medical Devices & Instruments industry, placing it in the top 55.8%.
Is Abbott Laboratories' EV-to-FCF too high?
Abbott Laboratories' current EV-to-FCF of 25.93 is 21% below median its 10-year median of 32.92. Over the past 10 years, this metric has ranged from a low of 20.42 to a high of 47.66. The Medical Devices & Instruments industry median EV-to-FCF is 22.82. Abbott Laboratories' value of 25.93 is 13.6% above this industry median. Based on the distribution chart, Abbott Laboratories ranks #235 out of 421 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Abbott Laboratories has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' EV-to-FCF compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #235 out of 421 companies for EV-to-FCF. This places Abbott Laboratories in the lower half of its industry. The industry median EV-to-FCF is 22.82. Abbott Laboratories' value of 25.93 is 13.6% above this benchmark. Historically, Abbott Laboratories' own EV-to-FCF has ranged from 20.42 to 47.66 over the past decade. While the company's 10-year median is 32.92 vs. the industry median of 22.82, Abbott Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.82, based on 421 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories's current EV-to-FCF of 25.93 is 13.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Abbott Laboratories and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories's current EV-to-FCF is 25.93, which is 21% below median its own 10-year median of 32.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (ABT) is currently considered Modestly Undervalued. The stock's GF Value™ is $129.49, compared to a current price of $94.12 — trading 27.3% below its estimated fair value. The current EV-to-FCF is 25.93, which is 21% below median its 10-year median of 32.92 and 13.6% above the Medical Devices & Instruments industry median of 22.82. Abbott Laboratories' overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Abbott Laboratories (ABT), the current EV-to-FCF is 25.93 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of $94.12 is trading 27.3% below its estimated GF Value™ of $129.49.
GuruFocus considers Abbott Laboratories to be Modestly Undervalued.
Key valuation signals for ABT:
EV-to-FCF: 25.93 (21% below median its 10-year median of 32.92)
GF Value™: $129.49 vs. price of $94.12 (27.3% below fair value)
Industry Position: 13.6% above the Medical Devices & Instruments median (#235 of 421)
No single metric tells the full story. See the ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
80GF Score
Get the complete analysis for ABT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABT has been successfully added to your 
